selegiline has been researched along with Neurodegenerative Diseases in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V | 1 |
| Borges, F; Fonseca, A; Gaspar, A; Milhazes, N; Reis, J; Uriarte, E; Viña, D | 1 |
| Legoabe, LJ; Petzer, A; Petzer, JP | 1 |
| Akkari, R; Borrmann, T; Brunschweiger, A; Drabczyńska, A; Hockemeyer, J; Kieć-Kononowicz, K; Koch, P; Köse, M; Küppers, P; Müller, CE; Radjainia, H; Schlenk, M | 1 |
| Adolph, O; Appenroth, D; Enzensperger, C; Fleck, C; Föhr, KJ; Gaube, F; Lehmann, J; Otto, R; Penzis, R; Robaa, D; Warncke, P; Winckler, T | 1 |
| Chew, ZX; Chye, SM; Koh, RY; Lim, CL; Ling, APK; Ng, KY | 1 |
| Maruyama, W; Naoi, M; Shamoto-Nagai, M | 1 |
| Ferdinandy, P; Fürst, S; Gyires, K; Miklya, I; Muraoka, S; Yoneda, F | 1 |
| Klivényi, P; Rákóczi, K; Vécsei, L | 1 |
| Miklya, I | 1 |
| Schneemilch, C | 1 |
| Brown-Borg, H; Carlson, EC; Ebadi, M; El ReFaey, H; Ren, J; Sharma, S; Shavali, S | 1 |
| Jenei, V; Magyar, K; Pálfi, M; Szöko, E | 1 |
| Mackowiak, A; Müller, T; Przuntek, H; Rieks, M | 1 |
| Czub, M; Czub, S; Gerlach, M; Gosztonyi, G; Koutsilieri, E; Müller, JG; Riederer, P; Sopper, S; ter Meulen, V | 1 |
| Arányi, P; Baranyi, A; Erdö, F; Takács, J | 1 |
| Chalmers-Redman, RM; Elstner, M; Jagodzinski, FB; Leesch, W; Stupak, DP; Sugrue, MM; Tatton, NA; Tatton, WG | 1 |
| Bhavnani, BR; Thomas, P; Thomas, T | 1 |
7 review(s) available for selegiline and Neurodegenerative Diseases
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid | 2008 |
Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies.
Topics: alpha-Synuclein; Glial Cell Line-Derived Neurotrophic Factors; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Neuroprotection; Neuroprotective Agents; Proto-Oncogene Proteins c-bcl-2; Selegiline; Synucleinopathies | 2022 |
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutrients; Nerve Degeneration; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Peptides; Selegiline; Tocopherols; Ubiquinone | 2009 |
[Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].
Topics: Aging; Apoptosis; Brain; Cell Culture Techniques; Humans; Mental Disorders; Neurodegenerative Diseases; Neuroprotective Agents; Selegiline | 2009 |
Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases.
Topics: Animals; Humans; Nervous System Diseases; Neurodegenerative Diseases; Selegiline | 2006 |
Deprenyl: from chemical synthesis to neuroprotection.
Topics: Animals; Humans; Neurodegenerative Diseases; Neuroprotective Agents; Selegiline | 2006 |
Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling.
Topics: Animals; Apoptosis; Brain; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Selegiline; Signal Transduction | 2000 |
11 other study(ies) available for selegiline and Neurodegenerative Diseases
| Article | Year |
|---|---|
Chromone 3-phenylcarboxamides as potent and selective MAO-B inhibitors.
Topics: Animals; Cell Line; Chromones; Humans; Inhibitory Concentration 50; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Protein Isoforms; Structure-Activity Relationship | 2011 |
Selected chromone derivatives as inhibitors of monoamine oxidase.
Topics: Benzopyrans; Chromones; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Parkinson Disease; Protein Isoforms; Recombinant Proteins; Structure-Activity Relationship | 2012 |
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine; CHO Cells; Cricetulus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Purinergic P1 Receptor Antagonists; Purines; Xanthines | 2013 |
Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
Topics: Animals; Carbolines; Cholinesterase Inhibitors; Computational Biology; Excitatory Amino Acid Antagonists; Humans; Indicators and Reagents; Ligands; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship | 2015 |
The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease - An Update.
Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Parkinson Disease; Selegiline | 2023 |
Geroprotection in the future. In memoriam of Joseph Knoll: The selegiline story continues.
Topics: Aging; Brain; Drug Development; Geriatrics; History, 20th Century; Humans; Life Expectancy; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Selegiline | 2020 |
[General anaesthesia for neurological diseases].
Topics: Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Intravenous; Autonomic Nervous System; Brain; Bromocriptine; Dopamine Agonists; Humans; Intubation; Levodopa; Monoamine Oxidase Inhibitors; Muscle Relaxants, Central; Nervous System Diseases; Neurodegenerative Diseases; Neurosurgery; Parkinson Disease; Piperidines; Premedication; Preoperative Care; Propofol; Remifentanil; Selegiline; Stereotaxic Techniques; Syndrome | 2010 |
Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cisplatin; Drug Interactions; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neuroblastoma; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Selegiline; Time Factors | 2008 |
Effects of Selegiline in a retroviral rat model for neurodegenerative disease.
Topics: Animals; Animals, Newborn; Brain; Histocompatibility Antigens Class II; Humans; Leukemia Virus, Murine; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Rats; Rats, Inbred F344; Retroviridae Infections; RNA, Viral; Selegiline; Tumor Virus Infections | 1999 |
Different neurorescue profiles of selegiline and p-fluoro-selegiline in gerbils.
Topics: Animals; Brain Ischemia; Cell Survival; Dose-Response Relationship, Drug; Fluorine Compounds; Gerbillinae; Hippocampus; Male; Nerve Degeneration; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Pyramidal Cells; Reperfusion Injury; Selegiline | 2000 |
Inhibition of human LDL oxidation by the neuroprotective drug l-deprenyl.
Topics: Adult; Antioxidants; Arteriosclerosis; Blood; Copper; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Humans; Lipoproteins, LDL; Male; Middle Aged; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Plasma; Postmenopause; Selegiline; Sex Characteristics | 2002 |